Actuate therapeutics to participate in upcoming investor conferences in february

Chicago and fort worth, texas, feb. 06, 2025 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), today announced that daniel schmitt, president & chief executive officer of actuate will participate in the following upcoming investor conferences:
ACTU Ratings Summary
ACTU Quant Ranking